Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

ABSTRACT:

Objective

To determine the baseline predictors of visual acuity (VA) outcomes 1 year after treatment with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD).

Design

Cohort study within the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Participants

A total of 1105 participants with neovascular AMD, baseline VA 20/25 to 20/320, and VA measured at 1 year.

Methods

Participants were randomly assigned to ranibizumab or bevacizumab on a monthly or as-needed schedule. Masked readers evaluated fundus morphology and features on optical coherence tomography (OCT). Visual acuity was measured using electronic VA testing. Independent predictors were identified using regression techniques.

Main outcome measures

SUBMITTER: Ying GS 

PROVIDER: S-EPMC3536921 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature